methyl 1-(dimethylcarbamoyl)piperidine-4-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: methyl 1-(dimethylcarbamoyl)piperidine-4-carboxylate
• 英文别名: 1-dimethylcarbamoyl-piperidine-4-carboxylic acid methyl ester；1-Dimethylcarbamoyl-piperidin-4-carbonsaeure-methylester；methyl 1-[(dimethylamino)carbonyl]piperidine-4-carboxylate
• 化学式: C₁₀H₁₈N₂O₃
• mdl: MFCD06154353
• 分子量: 214.265
• InChiKey: MKBINFIMENKFNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 1-(dimethylcarbamoyl)piperidine-4-carboxylate 在 甲醇 、 sodium hydroxide 作用下， 以56%的产率得到1-[(二甲基氨基)羰基]哌啶-4-羧酸
  参考文献：
  名称：

  WO2018211275A5

  摘要：

  公开号：

  WO2018211275A5
• 作为产物：
  描述：

  4-哌啶甲酸甲酯 、 二甲氨基甲酰氯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以17%的产率得到methyl 1-(dimethylcarbamoyl)piperidine-4-carboxylate
  参考文献：
  名称：

  WO2018211275A5

  摘要：

  公开号：

  WO2018211275A5

文献信息

• Fused Triazole Tachykinin Receptor Antagonists
  申请人：DeVita Robert J.

  公开号：US20090221611A1

  公开（公告）日：2009-09-03

  The present invention is directed to certain fused triazole compounds which are useful as neurokinin-1 (NK-I) receptor antagonists, and inhibitors of tachykinin and in particular substance P- The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

  本发明涉及某些融合的三唑化合物，它们可用作神经激肽-1（NK-I）受体拮抗剂和快速激肽，特别是物质P的抑制剂。本发明还涉及包含这些化合物作为活性成分的制药配方以及这些化合物及其配方在治疗某些疾病，包括呕吐、尿失禁、抑郁症和焦虑症方面的用途。
• Chemotherapy of Experimental Tuberculosis. VIII. The Synthesis of Acid Hydrazides, their Derivatives and Related Compounds^1,2
  作者：Harry L. Yale、Kathryn Losee、Joseph Martins、Mary Holsing、Frances M. Perry、Jack Bernstein

  DOI：10.1021/ja01104a046

  日期：1953.4
• WO2007/81897
  申请人：——

  公开号：——

  公开（公告）日：——
• COMPOUNDS
  申请人：The University Of Sheffield

  公开号：EP3628045A1

  公开（公告）日：2020-04-01
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：UNIV SHEFFIELD

  公开号：WO2018211275A1

  公开（公告）日：2018-11-22

  Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds;and intermediates useful in the preparation of the compounds.